IR Banner

Press Releases

Date Title and Summary Additional Format
Aug 2, 2021
Lumos Pharma Announces the Promotion of COO and Chief Scientific Officer, John McKew, PhD, to President
AUSTIN, Texas , Aug. 02, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, has announced that current Chief Operating Officer and Chief Scientific Officer, John McKew , PhD, was promoted to President of
Jul 26, 2021
Lumos Pharma Appoints Pediatric Endocrinologist Experienced in Clinical Research and Pharmaceutical Development, Mark Bach, M.D., Ph.D., to Clinical Scientific Advisory Board
AUSTIN, Texas , July 26, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that Mark Bach , M.D., Ph.D., accepted his appointment to the Company’s Clinical Scientific Advisory Board (CSAB)
Jul 22, 2021
Lumos Pharma to Report Second Quarter 2021 Financial Results and Host Conference Call on August 5, 2021
AUSTIN, Texas , July 22, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report its second quarter 2021 financial results before market open on Thursday, August 5, 2021 .
Jul 20, 2021
Lumos Pharma Announces Clinical Updates
OraGrowtH210 Trial in PGHD primary outcome 6-month data now anticipated in 2H2023; treatment period to be extended to 12 months OraGrowtH212 PK/PD Trial initiated in Q2 2021; treatment period to be extended to 12 months with primary data at 6-months Cash balance as of June 30, 2021 of $107.7
Jun 28, 2021
Lumos Pharma Announces OraGrowtH212 Trial of LUM-201 in PGHD Is Open for Enrollment
Single-Center Phase 2 Trial to Study the Pharmacokinetics/Pharmacodynamics (PK/PD) and  Unique Pulsatile Mechanism of Action of LUM-201 at Two Dose Levels AUSTIN, Texas , June 28, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on
May 19, 2021
Lumos Pharma to Participate in the Jefferies Virtual Healthcare Conference
AUSTIN, Texas , May 19, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc.  (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will be participating in a fireside chat at the Jefferies Virtual Healthcare Conference on June 3,
May 13, 2021
Lumos Pharma to Participate in the Oppenheimer Rare & Orphan Disease Summit
AUSTIN, Texas , May 13, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc.  (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will be presenting at the Oppenheimer Rare & Orphan Disease Summit on Friday, May 21, 2021 and will be
May 5, 2021
Lumos Pharma Reports First Quarter 2021 Financial Results and Provides Clinical and Corporate Updates
Newly released PK/PD data from prior study in PGHD support endogenous LUM-201 MOA and use of Predictive Enrichment Markers (PEMs) to identify patients likely to respond to LUM-201 Data presented at ENDO 2021 differentiate LUM-201 from standard GH secretagogues and show its potential to stimulate
Apr 28, 2021
Lumos Pharma to Report First Quarter 2021 Financial Results and Host Conference Call on May 5, 2021
AUSTIN, Texas , April 28, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report its first quarter 2021 financial results after market close on Wednesday, May 5, 2021 .
Apr 27, 2021
Newly Released Data on Three PGHD Patients Treated with LUM-201 in Prior Phase 2 Study To Be Presented in Lumos Pharma Key Opinion Leader Webinar
Virtual KOL Event is scheduled for Today, April 27th @ 10:30 AM ET AUSTIN, Texas , April 27, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced that new data highlights from three patients
Displaying 51 - 60 of 88